Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her-2 Negative Metastatic Breast Cancer
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically confirmed adenocarcinoma of the breast that is either TNBC or HER-2 negative.
    2. Received 0-2 lines of cytotoxic chemotherapy for metastatic breast cancer endocrine therapy and/or targeted therapy is allowed.
    3. Must have less than or equal to Grade 1 pre-existing peripheral neuropathy (as per CTCAE).

You may not be eligible for this study if the following are true:

    1. Hypersensitivity to pembrolizumab or any of its excipients.
    2. Has a known additional malignancy that progressed or required treatment within the last five years (exception:  basal cell carcinoma of the skin or squamous cell carcinoma of the skin or in situ cervical cancer)
    3. Patients with known active central nervous system metastases and/or carcinomatous meningitis
    4. Taxane therapy within 3 months.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.